ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Tuesday, November 19, 2024

11:00AM-12:30PM: Abstract Number: 2674

Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States

Abstracts: RA – Treatment II: Refining Use of Established Therapies

11:00AM-12:30PM: Abstract Number: 2693

Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2670

Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2671

Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial

Abstracts: RA – Treatment II: Refining Use of Established Therapies

11:00AM-12:30PM: Abstract Number: 2682

The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2666

The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II

11:00AM-12:30PM: Abstract Number: 2687

Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

11:00AM-12:30PM: Abstract Number: 2680

Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

11:00AM-12:30PM: Abstract Number: 2676

Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study

Abstracts: RA – Treatment II: Refining Use of Established Therapies

11:00AM-12:30PM: Abstract Number: 2691

Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2692

Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis

Abstracts: Vasculitis – ANCA-Associated II

11:00AM-12:30PM: Abstract Number: 2675

Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial

Abstracts: RA – Treatment II: Refining Use of Established Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].